GSK plc (NYSE:GSK) Shares Sold by Snowden Capital Advisors LLC

Snowden Capital Advisors LLC lessened its holdings in shares of GSK plc (NYSE:GSK) by 74.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,030 shares of the pharmaceutical company’s stock after selling 20,341 shares during the quarter. Snowden Capital Advisors LLC’s holdings in GSK were worth $247,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Indiana Trust & Investment Management Co increased its position in GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Crews Bank & Trust acquired a new stake in GSK during the 4th quarter worth approximately $26,000. Sierra Ocean LLC acquired a new stake in GSK during the 4th quarter worth approximately $32,000. Parkside Financial Bank & Trust increased its position in GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock worth $34,000 after purchasing an additional 818 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new stake in GSK during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Performance

GSK stock opened at $38.91 on Friday. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.77. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The stock has a market cap of $80.28 billion, a P/E ratio of 24.47, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The stock has a 50 day moving average of $37.31 and a 200-day moving average of $36.01.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.05. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter last year, the company earned $0.43 earnings per share. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 dividend on an annualized basis and a dividend yield of 4.33%. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is presently 86.60%.

Analyst Ratings Changes

A number of analysts recently issued reports on GSK shares. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Hsbc Global Res upgraded GSK to a “strong sell” rating in a report on Monday, April 28th. Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 24th. Finally, BNP Paribas began coverage on GSK in a report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 price target for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, GSK has an average rating of “Moderate Buy” and an average target price of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.